Table 5.
Current CAR-T cell clinical trials for thoracic malignancies.
| Target Antigen | Indication | Phase | Location | Status | NCT# |
|---|---|---|---|---|---|
| CEA | Lung, Colorectal, Gastric, Breast, Pancreatic |
I | China | Recruiting | NCT02349724 |
| EGFR | Cholangiocarcinoma, Colorectal, NSCLC, Ovarian, Pancreatic, Renal | I/II | China | Recruiting | NCT01869166 |
| FAP | Mesothelioma | I | Zurich | Recruiting | NCT01722149 |
| GD2 | Solid tumors | I/II | China | Recruiting | NCT02992210 |
| GPC3 | Hepatocellular Carcinoma, Squamous Cell Lung | I | China | Recruiting | NCT03198546 |
| GPC3 | Lung Squamous Cell Carcinoma | I | China | Recruiting | NCT02876978 |
| HER2 | Breast, Ovarian, Lung, Gastric, Colorectal, Glioma, Pancreatic | I/II | China | Recruiting | NCT02713984 |
| MSLN | Lung Adenocarcinoma, Ovarian, Peritoneal Carcinoma, Mesotheliomas | I | UPENN | Active, not recruiting | NCT03054298 |
| MSLN | Cervical, Pancreatic, Ovarian, Mesothelioma, Lung | I/II | NCI | Recruiting | NCT01583686 |
| MSLN | Breast, Lung, Malignant Pleural Disease, Mesothelioma, Metastases | I | MSKCC | Recruiting | NCT02414269 |
| MSLN | Breast, Endometrial, Mesothelioma, Ovarian, Pancreatic | I | China | Recruiting | NCT02580747 |
| MSLN | Mesothelioma, Pancreatic, Ovaria, Metastatic | I | UPENN | Complete | NCT02159716 |
| MSLN | Mesothelioma | I | UPENN | Complete | NCT01355965 |
| MUC1 | Lung Neoplasm Malignant, NSCLC | I/II | China | Recruiting | NCT03525782 |
| MUC1 | Hepatocellular Carcinoma, NSCLC, Pancreatic, Triple-Negative Invasive Breast Carcinoma, Malignant Glioma, Colorectal, Gastric | I/II | China | Recruiting | NCT02587689 |
| MUC1 | Hepatocellular Carcinoma, NSCLC, Pancreatic Carcinoma Triple-Negative Invasive Breast Carcinoma, Malignant Glioma of Brain, Colorectal, Gastric | I/II | China | Recruiting | NCT02839954 |
| PD1 | Gastric, Lung, Liver | I/II | China | Recruiting | NCT02862028 |
| PDL1 | NSCLC | I | China | Not yet recruiting | NCT03330834 |
| PSCA/MUC1/PDL1/CD80/86 | Lung | I | China | Recruiting | NCT03198052 |
| ROR1 | Breast (including triple negative), Leukemias (ALL, CLL, mantle cell), NSCLC | I | NCI | Recruiting | NCT02706392 |
| VEGF Receptor 2 | Melanoma, Renal, Metastatic | I/II | NCI | Complete | NCT01218867 |
Key: Carcinoembryonic Antigen (CEA), Epidermal Growth Factor (EGFR), Fibroblast Activation Protein (FAP), Ganglioside (GD2), Glypican-3 (GPC3), Human Epidermal Growth Factor 2 (HER2), Mesothelin (MSLN), Transmembrane Glycoprotein Mucin 1 (MUC1), Program Cell Death Protein 1 (PD1), Programmed Cell Death Ligand 1 (PDL1), Prostate Stem Cell Antigen (PSCA), Vascular Endothelial Growth Factor (VEGF).